Suchen
Brainstorm Cell Therapeutics Inc
BCLIZur Watchlist hinzufügen
1.170USD
0.0000.00%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
9.26MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Brainstorm Cell Therapeutics Inc Unternehmen
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Brainstorm Cell Therapeutics Inc Informationen
BörsenkürzelBCLI
Name des UnternehmensBrainstorm Cell Therapeutics Inc
IPO-datumMay 28, 2003
CEOMr. Chaim Lebovits
Anzahl der mitarbeiter27
WertpapierartOrdinary Share
GeschäftsjahresendeMay 28
Addresse1325 Avenue Of Americas
StadtNEW YORK
BörseUS 'Other OTC' and Grey Market
LandUnited States of America
Postleitzahl10019
Telefon12014880460
Websitehttps://brainstorm-cell.com/
BörsenkürzelBCLI
IPO-datumMay 28, 2003
CEOMr. Chaim Lebovits
Führungskräfte von Brainstorm Cell Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+2.07%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+12.18%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+2.07%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+12.18%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Brainstorm Cell Therapeutics Inc?
Die fünf größten Anteilseigner von Brainstorm Cell Therapeutics Inc sind: Mr. Uri Yablonka
Wie viele Institutionen halten Anteile an Brainstorm Cell Therapeutics Inc (BCLI)?
Mit Stand vom 2026Q1 halten 77 Institutionen Anteile an Brainstorm Cell Therapeutics Inc, mit einem Gesamtmarktwert von etwa 400.00, was 0.01% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1195352.00 gestiegen.